Detection and monitoring of cancer biomarkers using digital PCR
Digital PCR is an end-point PCR that allows the absolute quantification of rare events in a biological sample. In oncology, we are interested in follow-ups on the evolution of cancer cells after treatment and detecting biomarkers for the diagnosis and prognosis of cancer. We are currently exploring the utilities of dPCR in follow-ups of JAK2 mutation in cases of essential thrombocythemia (ET) and the quantification of CAR-T cells in leukemia.
About the speaker
Liza Ho, Research Scientist
University Hospital of Geneva
Liza Ho is a Research Scientist at the University Hospital of Geneva. She completed her Bachelor of Biochemistry at the Imperial College London and Ph.D. in Biochemistry at the University of Cambridge. In 1992, she joined the Institute of Cancer Research, Royal Marsden Hospital, London, as a Research Scientist, followed by a similar role at the Theodor Kocher Institute, Bern, Switzerland starting in 1997. Since 2000, she has been responsible for research and development in the Laboratory of Molecular Pathology, Department of Clinical Pathology, University Hospital of Geneva. She received a parallel Master's in Public Health degree from the University of Geneva in 2006
Categories
Oncology
dPCR
Digital PCR